Testicular germ cell tumors: Biology and clinical update

Current Opinion in Oncology

Volumn 25, Issue 3, 2013, Pages 266-272

  Nallu, Anitha ^a   Mannuel, Heather D ^a   Hussain, Arif ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

germ cell tumor; molecular studies; radiotherapy; retroperitoneal lymph node dissection; surveillance

Indexed keywords

ALPHA FETOPROTEIN; CANNABINOID; CARBOPLATIN; CASPASE 3; CASPASE 8; CASPASE 9; CD147 ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; CURCUMIN; CYTOCHROME C; DNA METHYLTRANSFERASE 3B; DOUBLESEX AND MAB 3 RELATED TRANSCRIPTION FACTOR 1; METAL; PROTEIN BAX; PROTEIN BCL 2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CAUSE SPECIFIC SURVIVAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG EXPOSURE; GENE EXPRESSION; GENE LOCUS; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GERM CELL TUMOR; HOMOZYGOTE; HUMAN; LYMPH NODE DISSECTION; OLIGOSPERMIA; PATIENT CARE; PHOTON THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SEMINOMA; SINGLE NUCLEOTIDE POLYMORPHISM; SPERMATOGENESIS; TREATMENT OUTCOME;

HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; TESTICULAR NEOPLASMS;

EID: 84876294360     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835ff3e3     Document Type: Review

References (25)

1. Rosen A, Jayram G, Drazer M, Eggener SE. Global trends in testicular cancer incidence and mortality. Eur Urol 2011; 60:374-379.
2. Maule M, Malavassi JL, Richiardi L Age at puberty and risk of testicular cancer: a meta-analysis. Int J Androl 2012; 35:828-834.
3. Lacson JC, Carroll JD, Tuazon E, et al. Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk. Cancer 2012; 118:5374-5383.
4. Behrens T, Pohlabeln H, Mester B, et al. Exposure to metal-working fluids in the automobile industry and the risk of male germ cell tumours. Occup Environ Med 2012; 69:224-226.
5. Arora RS, Alston RD, Eden TO, et al. Comparative incidence patterns and trends of gonadal and extragonadal germ cell tumors in England, 1979 to 2003. Cancer 2012; 118:4290-4297.
6. Kanetsky PA, Mitra N, Vardhanabhuti S, et al. A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility. Hum Mol Genet 2011; 20:3109-3117.
7. Ferlin A, Pengo M, Pizzol D, et al. Variants in KITLG predispose to testicular germ cell cancer independently from spermatogenic function. Endocr Relat Cancer 2012; 19:101-108.
8. Lessel D, Gamulin M, Kulis T, et al. Replication of genetic susceptibility loci for testicular germ cell cancer in the Croatian population. Carcinogenesis 2012; 33:1548-1552.
9. Davis-Dao CA, Siegmund KD, Vandenberg DJ, et al. Heterogenous effect of androgen receptor CAG tract length on testicular germ cell tumor risk: shorter repeats associated with seminoma but not other histologic types. Carcinogenesis 2011; 32:1238-1243.
10. Kristiansen W, Aschim EL, Andersen JM, et al. Variations in testosterone pathway genes and susceptibility to testicular cancer in Norwegian men. Int J Androl 2012; 35:819-827.
11. Novotny GW, Belling KC, Bramsen JB, et al. MicroRNA expression profiling of carcinoma in situ cells of the testis. Endocr Relat Cancer 2012; 19:365-379.
12. Bi XC, Liu JM, He HC, et al. Extracellular matrix metalloproteinase inducer: a novel poor prognostic markerfor human seminomas. Clin Transl Oncol 2012; 14:190-196.
13. Arai E, Nakagawa T, Wakai-Ushijima S, et al. DNA methyltransferase 3B expression is associated with poor outcome of stage I testicular seminoma. Histopathology 2012; 60:E12-E18.
14. Aparicio J, Maroto P, del Muro XG, et al. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol 2012; 30:2021.
15. Heinzelbecker J, Katzmarzik M, Weiss C, et al. Changes of stage, predictive factors and adjuvant treatment modalities in seminomatous testicular cancer from 1987 to 2007 and their impact on the status of metastasis, recurrence-free and overall survival: a single-center analysis. Urol Int 2011; 87:282-287.
16. Jones G, Arthurs B, Kaya H, et al. Overall survival analysis of adjuvant radiation versus observation in stage I testicular seminoma: a Surveillance, Epidemiology, and End Results (SEER) analysis. Am J Clin Oncol. 2012. [Epub ahead of print]
17. Lewinshtein D, Gulati R, Nelson PS, Porter CR. Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma. BJU Int 2012; 109:706-712.
18. Simone CB 2nd, Kramer K, O'Meara WP, et al. Predicted rates of secondary malignancies from proton versus photon radiation therapy for stage I seminoma. Int J Radiat Oncol Biol Phys 2012; 82:242-249.
19. Cort A, Timur M, Ozdemir E, et al. Synergistic anticancer activity of curcumin and bleomycin: an in vitro study using human malignant testicular germ cells. J Physiol Biochem 2012. [Epub ahead of print]
20. Koychev D, Oechsle K, Bokemeyer C, Honecker F. Treatment of patients with relapsed and/or cisplatin-refractory metastatic germ cell tumours: an update. Int J Androl 2011; 34:e266-e273.
21. Masterson TA, Shayegan B, Carver BS, et al. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. Urology 2012; 79:156-159.
22. Busch J, Magheli A, Erber B, et al. Laparoscopic and open postchemotherapy retroperitoneal lymph node dissection in patients with advanced testicular cancer: a single center analysis. BMC Urol 2012; 12:15.
23. Hudolin T, Kastelan Z, Knezevic N, et al. Correlation between retroperitoneal lymph node size and presence of metastases in nonseminomatous germ cell tumors. Int J Surg Pathol 2012; 20:15-18.
24. Masterson TA, Carver BS, Abel EJ, et al. Impact of age on clinicopathological outcomes and recurrence-free survival after the surgical management of nonseminomatous germ cell tumour. BJU Int 2012; 110:950-955.
25. Keskin S, Ekenel M, Basaran M, Bavbek S. Predictive value of marker half-life in relapsed and nonrelapsed nonseminomatous germ cell testicular tumor patients undergoing chemotherapy. Am J Clin Oncol 2012; 35:369-372.